Literature DB >> 28165299

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

Antonia R Sepulveda1, Stanley R Hamilton1, Carmen J Allegra1, Wayne Grody1, Allison M Cushman-Vokoun1, William K Funkhouser1, Scott E Kopetz1, Christopher Lieu1, Noralane M Lindor1, Bruce D Minsky1, Federico A Monzon1, Daniel J Sargent1, Veena M Singh1, Joseph Willis1, Jennifer Clark1, Carol Colasacco1, R Bryan Rumble1, Robyn Temple-Smolkin1, Christina B Ventura1, Jan A Nowak1.   

Abstract

Purpose Molecular testing of colorectal cancers (CRCs) to improve patient care and outcomes of targeted and conventional therapies has been the center of many recent studies, including clinical trials. Evidence-based recommendations for the molecular testing of CRC tissues to guide epidermal growth factor receptor (EGFR) -targeted therapies and conventional chemotherapy regimens are warranted in clinical practice. The purpose of this guideline is to develop evidence-based recommendations to help establish standard molecular biomarker testing for CRC through a systematic review of the literature. Methods The American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to develop an evidence-based guideline to help establish standard molecular biomarker testing, guide targeted therapies, and advance personalized care for patients with CRC. A comprehensive literature search that included over 4,000 articles was conducted to gather data to inform this guideline. Results Twenty-one guideline statements (eight recommendations, 10 expert consensus opinions and three no recommendations) were established. Recommendations Evidence supports mutational testing for genes in the EGFR signaling pathway, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize molecular testing for predictive and prognostic molecular biomarkers involve selection of assays, type of specimens to be tested, timing of ordering of tests and turnaround time for testing results. Additional information is available at: www.asco.org/CRC-markers-guideline and www.asco.org/guidelineswiki.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28165299     DOI: 10.1200/JCO.2016.71.9807

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  93 in total

1.  Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Authors:  Krittiya Korphaisarn; Chao-Kai Chou; Wei-Ya Xia; Callisia N Clarke; Riham Katkhuda; Jennifer S Davis; Kanwal Ps Raghav; Hsin-Wei Liao; Ji-Yuan Wu; David G Menter; Dipen M Maru; Mien-Chie Hung; Scott Kopetz
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 2.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

3.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Authors:  Jonathan M Loree; Allan A L Pereira; Michael Lam; Alexandra N Willauer; Kanwal Raghav; Arvind Dasari; Van K Morris; Shailesh Advani; David G Menter; Cathy Eng; Kenna Shaw; Russell Broaddus; Mark J Routbort; Yusha Liu; Jeffrey S Morris; Rajyalakshmi Luthra; Funda Meric-Bernstam; Michael J Overman; Dipen Maru; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2017-11-27       Impact factor: 12.531

Review 4.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

Review 5.  Rectal Cancer in 2018: A Primer for the Gastroenterologist.

Authors:  Benjamin A Goldenberg; Emma B Holliday; Ramzi M Helewa; Harminder Singh
Journal:  Am J Gastroenterol       Date:  2018-12       Impact factor: 10.864

6.  Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.

Authors:  Y Nancy You; Ester Borras; Kyle Chang; Brandee A Price; Maureen Mork; George J Chang; Miguel A Rodriguez-Bigas; Brian K Bednarski; Funda Meric-Bernstam; Eduardo Vilar
Journal:  Dis Colon Rectum       Date:  2019-04       Impact factor: 4.585

Review 7.  Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Authors:  Amir Mehrvarz Sarshekeh; Michael J Overman; Scott Kopetz
Journal:  Future Oncol       Date:  2018-02-23       Impact factor: 3.404

Review 8.  Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial.

Authors:  Joseph D Khoury; Wei-Lien Wang; Victor G Prieto; L Jeffrey Medeiros; Neda Kalhor; Meera Hameed; Russell Broaddus; Stanley R Hamilton
Journal:  Clin Cancer Res       Date:  2017-08-24       Impact factor: 12.531

Review 9.  Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Danny A Milner; Reiko Nishihara
Journal:  Annu Rev Pathol       Date:  2018-08-20       Impact factor: 23.472

10.  Clinical validation of coexisting driver mutations in colorectal cancers.

Authors:  Gang Zheng; Li-Hui Tseng; Lisa Haley; Junaid Ibrahim; Jennifer Bynum; Rena Xian; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Hum Pathol       Date:  2018-11-24       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.